Vanguard Group
ATXI

Vanguard Group’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Vanguard Group’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-617
Closed -$6.83K – 4449
2024
Q1 		$6.83K Hold
617
– – ﹤0.01% 4437
2023
Q4 		$7.45K Hold
617
– – ﹤0.01% 4485
2023
Q3 		$32.7K Buy
+617
New +$43.6K ﹤0.01% 4457
2022
Q3 		– Sell
-117
Closed -$36K – 4612
2022
Q2 		$36K Sell
117
-285
-71% -$110K ﹤0.01% 4599
2022
Q1 		$218K Hold
402
– – ﹤0.01% 4524
2021
Q4 		$411K Hold
402
– – ﹤0.01% 4463
2021
Q3 		$675K Buy
402
+2
+0.5% +$4.13K ﹤0.01% 4329
2021
Q2 		$1.13M Sell
400
-221
-36% -$1.09M ﹤0.01% 4125
2021
Q1 		$4.24M Sell
621
-214
-26% -$1.47M ﹤0.01% 3615
2020
Q4 		$5.59M Buy
835
+262
+46% +$1.37M ﹤0.01% 3312
2020
Q3 		$6.98M Buy
573
+192
+50% +$2.33M ﹤0.01% 2979
2020
Q2 		$4.62M Buy
381
+108
+40% +$1.22M ﹤0.01% 3133
2020
Q1 		$2.75M Buy
273
+124
+83% +$1.24M ﹤0.01% 3212
2019
Q4 		$1.61M Buy
149
+27
+22% +$189K ﹤0.01% 3507
2019
Q3 		$819K Buy
122
+34
+39% +$232K ﹤0.01% 3700
2019
Q2 		$625K Hold
88
– – ﹤0.01% 3789
2019
Q1 		$471K Buy
88
+26
+42% +$166K ﹤0.01% 3786
2018
Q4 		$379K Sell
62
-25
-29% -$120K ﹤0.01% 3790
2018
Q3 		$279K Sell
87
-1
-1% -$4.11K ﹤0.01% 3954
2018
Q2 		$353K Buy
88
+4
+5% +$18.6K ﹤0.01% 3889
2018
Q1 		$427K Buy
84
+45
+115% +$223K ﹤0.01% 3815
2017
Q4 		$161K Buy
39
+17
+77% +$86.7K ﹤0.01% 3958
2017
Q3 		$136K Buy
+22
New +$162K ﹤0.01% 3965

Other funds holding ATXI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group's ATXI Position: Q2 2024 in Review

Vanguard Group sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 617 shares — an estimated $6.83K sold.

Vanguard Group first reported a position in ATXI in Q3 2017 and held it in 23 quarters. The position peaked at $6.98M in Q3 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

  • Vanguard Group reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Vanguard Group sold 617 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $6.83K.
  • Vanguard Group first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2017 and held it in 23 quarters.
  • Vanguard Group's Avenue Therapeutics, Inc. Common Stock position peaked at $6.98M in Q3 2020.
  • 9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.